Drugs / Purinostat
Purinostat
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05526313 | Aug 2020 → Sep 2022 | diffuse large B-cell lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06431243 | May 2024 → May 2026 overdue | neoplasm | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06484829 | Mar 2024 → Feb 2026 overdue | refractory plasma cell neoplasm | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06485219 | Apr 2024 → Jun 2026 overdue | peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05563844 | Nov 2022 → Dec 2026 expected | diffuse large B-cell lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07011056 | Jul 2025 → Jun 2029 expected | diffuse large B-cell lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Purinostat | “Purinostat mesylate for injection (PM) was the novel and highly potent Class Ia and IIb HDAC selective inhibitor.” NCT05563844 ↗ |
| Known as | Purinostat Mesylate | “A Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of the Purinostat Mesylate for Injection (PM) Compared to Selinexor in...” NCT07011056 ↗ |
| Known as | Purinostat Mesylate for Injection | “Purinostat mesylate for injection (PM) was the novel and highly potent Class Ia and IIb HDAC selective inhibitor.” NCT05563844 ↗ |
| Action | Inhibit | “IC50 values of PM for inhibiting HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10 subtypes of HDAC class I and HDAC class IIb” NCT05526313 ↗ |
| Route | Intravenous | “after single and multiple intravenous infusions of priinostat mesylate for injection” NCT05526313 ↗ |
| Target | HDAC1 | “The results of in vitro enzymatic activity screening showed that PM has high inhibitory activity on HDAC tumors (including HDAC1, 2, 3, 8 subtypes) and type II HDACs (including...” NCT05526313 ↗ |
| Target | HDAC6 | “The results of in vitro enzymatic activity screening showed that PM has high inhibitory activity on HDAC tumors (including HDAC1, 2, 3, 8 subtypes) and type II HDACs (including...” NCT05526313 ↗ |